Abstract:Middle East respiratory syndrome (MERS) is caused by a specific strain of the 6 types of human coronaviruses (HCoV). MERS-CoV has spread unchecked since it was first discovered in Saudi Arabia in 2012. The virus most likely spreads through nosocomial and zoonotic channels. Genetic analyses suggest that bats were the initial hosts and that the disease spread to camels. Person-to-person transmission occurs with varying frequency, being most prevalent in clinical settings and the least common among the general population and among close relatives. Due to the severity of the illness, high fatality rate, potential for epidemic spread, and lack of adequate medical countermeasures, the World Health Organization (WHO) continues to list MERS-CoV as a priority pathogen. While no specific antiviral medicines exist, a combination of antivirals has shown promise in recent clinical trials. Vaccines against MERS-CoV are critically needed and are currently being developed. Early diagnosis and implementing appropriate infection control measures are keys to preventing hospital-associated outbreaks. Preventive measures include avoiding raw or undercooked meats and other animal products, ensuring proper hand hygiene in healthcare settings and around dromedaries, educating the public and healthcare personnel about the disease, and adhering to other recommended practices. Countries with a high prevalence of MERS should adhere to regulations designed to limit the transmission of the virus. The recent spread of MERS-CoV highlights the importance of public awareness regarding the significance of reporting symptoms so that appropriate control measures can be adopted. The narrative review discusses the incidence of MERS, its clinical presentation, potential transmission routes, recent reports, preventative and control measures, and current therapeutic options.

Calling for rapid development of a safe and effective MERS vaccine.

Middle East Respiratory Syndrome: Current Status and Future Prospects for Vaccine Development

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development

Development of Middle East Respiratory Syndrome Coronavirus vaccines – advances and challenges

Antibodies And Vaccines Against Middle East Respiratory Syndrome Coronavirus

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Current Advancements and Potential Strategies in the Development of MERS-CoV Vaccines

Urgent Development of Effective Therapeutic and Prophylactic Agents to Control the Emerging Threat of Middle East Respiratory Syndrome (MERS)

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Middle East Respiratory Syndrome Coronavirus Could be a Priority Pathogen to Cause Public Health Emergency: Noticeable Features and Counteractive Measures

From SARS to MERS: Evidence and Speculation

Middle East Respiratory Syndrome Coronavirus (Mers-Cov): Challenges in Identifying Its Source and Controlling Its Spread

Receptor-binding domain-based subunit vaccines against MERS-CoV.

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV)

Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies

A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Rapid generation of a mouse model for Middle East respiratory syndrome

Coronavirus vaccine development: from SARS and MERS to COVID-19

[Small Molecular Agents Against MERS-CoV Infection].